Sean Wieland
Stock Analyst at Piper Sandler
(1.35)
# 3,407
Out of 4,876 analysts
29
Total ratings
40%
Success rate
-0.36%
Average return
Main Sectors:
Stocks Rated by Sean Wieland
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRVA Privia Health Group | Maintains: Overweight | $25 → $40 | $22.00 | +81.82% | 2 | Feb 28, 2025 | |
| OMCL Omnicell | Upgrades: Overweight | $70 → $39 | $29.38 | +32.74% | 11 | Nov 3, 2023 | |
| AMWL American Well | Maintains: Overweight | $100 → $120 | $7.94 | +1,411.34% | 2 | Jun 23, 2022 | |
| HIMS Hims & Hers Health | Maintains: Overweight | $8 → $6 | $49.41 | -87.86% | 3 | May 26, 2022 | |
| DOCS Doximity | Maintains: Overweight | $81 → $44 | $61.09 | -27.98% | 2 | May 19, 2022 | |
| IQV IQVIA Holdings | Maintains: Neutral | $261 → $231 | $157.47 | +46.69% | 4 | Feb 18, 2022 | |
| TDOC Teladoc Health | Maintains: Overweight | $305 → $291 | $8.41 | +3,360.17% | 5 | Feb 25, 2021 |
Privia Health Group
Feb 28, 2025
Maintains: Overweight
Price Target: $25 → $40
Current: $22.00
Upside: +81.82%
Omnicell
Nov 3, 2023
Upgrades: Overweight
Price Target: $70 → $39
Current: $29.38
Upside: +32.74%
American Well
Jun 23, 2022
Maintains: Overweight
Price Target: $100 → $120
Current: $7.94
Upside: +1,411.34%
Hims & Hers Health
May 26, 2022
Maintains: Overweight
Price Target: $8 → $6
Current: $49.41
Upside: -87.86%
Doximity
May 19, 2022
Maintains: Overweight
Price Target: $81 → $44
Current: $61.09
Upside: -27.98%
IQVIA Holdings
Feb 18, 2022
Maintains: Neutral
Price Target: $261 → $231
Current: $157.47
Upside: +46.69%
Teladoc Health
Feb 25, 2021
Maintains: Overweight
Price Target: $305 → $291
Current: $8.41
Upside: +3,360.17%